PMID- 25565768
OWN - NLM
STAT- PubMed-not-MEDLINE
DCOM- 20150108
LR  - 20220330
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 9
DP  - 2015
TI  - Prostaglandin-associated periorbitopathy in latanoprost users.
PG  - 51-6
LID - 10.2147/OPTH.S75651 [doi]
AB  - PURPOSE: We investigated the incidence of prostaglandin-associated 
      periorbitopathy (PAP) in subjects with glaucoma treated with latanoprost 
      ophthalmic solution. SUBJECTS AND METHODS: One eye and the forehead in 22 
      subjects were evaluated. All patients had used latanoprost for more than 1 year 
      (range, 12 to 45 months; mean, 26.0 months) and were prostaglandin F2alpha analogue 
      treatment-naive. Digital photographs of the subjects obtained before latanoprost 
      therapy and at the last examination were compared retrospectively. Four signs of 
      PAP (deepening of the upper eyelid sulcus (DUES), upper eyelid ptosis, flattening 
      of the lower eyelid bags, and inferior scleral show) and supplemental side 
      effects around the eyelids (eyelash growth, poliosis, and eyelid pigmentation) 
      were judged to be negative or positive by three independent observers. If the 
      observers unanimously rated a sign as positive, the result was defined as 
      positive. RESULTS: Twelve subjects (54.5%) had no apparent signs. Three subjects 
      were judged to have DUES (13.6%), and two subjects each were judged to have 
      flattening of the lower eyelid bags and eyelid pigmentation (9.0%). The other 
      signs were judged as positive in only one subject each, respectively (4.5%). A 
      univariate logistic regression analysis showed no significant associations 
      between any of the signs and age, sex, or the duration of therapy. CONCLUSION: 
      Latanoprost induced DUES, upper eyelid ptosis, flattening of the lower eyelid 
      bags, inferior scleral show, and supplemental side effects around the eyelids; 
      however, the rates of such occurrence might be relatively low.
FAU - Nakakura, Shunsuke
AU  - Nakakura S
AD  - Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
FAU - Yamamoto, Minamai
AU  - Yamamoto M
AD  - Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
FAU - Terao, Etsuko
AU  - Terao E
AD  - Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
FAU - Nagatomi, Nozomi
AU  - Nagatomi N
AD  - Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
FAU - Matsuo, Naoko
AU  - Matsuo N
AD  - Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
FAU - Fujisawa, Yausko
AU  - Fujisawa Y
AD  - Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
FAU - Fujio, Yuki
AU  - Fujio Y
AD  - Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
FAU - Tabuchi, Hitoshi
AU  - Tabuchi H
AD  - Department of Ophthalmology, Saneikai Tsukazaki Hospital, Himeji, Japan.
FAU - Kiuchi, Yoshiaki
AU  - Kiuchi Y
AD  - Department of Ophthalmology and Visual Sciences, Graduate School of Biomedical 
      Sciences, Hiroshima University, Hiroshima, Japan.
LA  - eng
PT  - Journal Article
DEP - 20141230
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC4284030
OTO - NOTNLM
OT  - deepening of the upper eyelid sulcus
OT  - glaucoma
OT  - prostaglandin F2alpha
EDAT- 2015/01/08 06:00
MHDA- 2015/01/08 06:01
PMCR- 2014/12/30
CRDT- 2015/01/08 06:00
PHST- 2015/01/08 06:00 [entrez]
PHST- 2015/01/08 06:00 [pubmed]
PHST- 2015/01/08 06:01 [medline]
PHST- 2014/12/30 00:00 [pmc-release]
AID - opth-9-051 [pii]
AID - 10.2147/OPTH.S75651 [doi]
PST - epublish
SO  - Clin Ophthalmol. 2014 Dec 30;9:51-6. doi: 10.2147/OPTH.S75651. eCollection 2015.